Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dupilumabum - solution injectable en seringue préremplie - dupilumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, saccharum, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - dermatite atopique modérée à sévère chez l’adulte, l'asthme à partir de 12 ans et la polypose naso-sinusienne - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents contre la dermatite, à l'exclusion des corticostéroïdes - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Canada - français - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 300mg - dupilumab 300mg - misc. skin and mucous membrane agents

Canada - français - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 200mg - dupilumab 200mg - misc. skin and mucous membrane agents

Canada - français - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 300mg - dupilumab 300mg - misc. skin and mucous membrane agents

Canada - français - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 200mg - dupilumab 200mg

Canada - français - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 100mg - dupilumab 100mg

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dupilumabum - solution injectable en seringue préremplie avec système de sécurité - dupilumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, natrii acetas trihydricus, acidum aceticum glaciale, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.67 ml, natrium 0.15 mg. - dermatite atopique modérée à sévère, asthme, polypose naso-sinusienne, prurigo nodularis et œsophagite à éosinophiles - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dupilumabum - solution injectable en seringue préremplie avec système de sécurité - dupilumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, saccharum, aqua ad iniectabile q.s. ad solutionem pro 2 ml corresp. natrium 0.45 mg. - dermatite atopique modérée à sévère, asthme, polypose naso-sinusienne, prurigo nodularis et œsophagite à éosinophiles - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dupilumabum - solution injectable en seringue préremplie avec système de sécurité - dupilumabum 200 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1.14 ml corresp. natrium 0.25 mg. - dermatite atopique modérée à sévère, asthme, polypose naso-sinusienne, prurigo nodularis et œsophagite à éosinophiles - biotechnologika